Many of these new secondary metabolites with different patterns of cyclizations showed significant inhibitory activity against human protein tyrosine phosphatase 1B(PTP1B) enzyme3, 4, 16, a promising drug target for the treatment of type 2 diabetes and obesity17. This evidence concerns the gene PTPN1 and type 2 diabetes mellitus.